Clinical Trials Logo

Filter by:
NCT ID: NCT06277466 Recruiting - Clinical trials for Type 2 Diabetes Mellitus

Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression. Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.

NCT ID: NCT06277453 Active, not recruiting - Clinical trials for Locally Advanced Gastric Cancer

Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy

Start date: January 1, 2023
Phase:
Study type: Observational

To explore the effect of adjuvant chemotherapy cycles on the prognosis of this specific patient with lymph node-negative gastric cancer following neoadjuvant chemotherapy.

NCT ID: NCT06277427 Recruiting - Lupus Nephritis Clinical Trials

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Start date: February 5, 2024
Phase: N/A
Study type: Interventional

Lupus nephritis (LN) and ANCA-associated vasculitis are severe autoimmune diseases, which may lead to the death of patients, particularly when they are refractory to the conventional therapeutic agents. Based on the current knowledge, the autoantibodies against self-antigens may exert important pathological roles in the pathogenesis of both LN and ANCA-associated vasculitis, of which the origins are primarily plasmablasts and plasma cells. BCMA is the molecule expressed on memory B cells, plasmablasts and plasma cells, and therefore is an ideal target for the elimination of potential pathogenic antibody secreting cells. Chimeric antigen receptor (CAR) T cells against BCMA may provide a novel therapeutic way for the refractory LN and ANCA-associated vasculitis patients to eliminate the pathogenic autoantibody-secreting cells. In this study, the safety and efficacy of a novel CAR-T cell therapy using PRG-1801 cells, are evaluated in patients with refractory LN and ANCA-associated vasculitis.

NCT ID: NCT06277414 Recruiting - Clinical trials for Endoscopic Retrograde Cholangiopancreatography

a Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Complication

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

To develop effective preoperative and postoperative prediction models for postoperative complications of ERCP

NCT ID: NCT06277388 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.

Start date: June 5, 2021
Phase:
Study type: Observational

This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent combined concurrent chemoradiotherapy (CCRT) and immunotherapy. Additionally, It sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.

NCT ID: NCT06277284 Active, not recruiting - Pharmacokinetics Clinical Trials

Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

Start date: October 23, 2023
Phase: N/A
Study type: Interventional

Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults

NCT ID: NCT06277245 Recruiting - Atopic Dermatitis Clinical Trials

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Start date: February 6, 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind study comparing LNK01001 to placebo in participants with moderately to severely atopic dermatitis who were candidates for systemic therapy (ie, patients with a history of inadequate response to topical treatments, those who were using a systemic treatment, or those for whom topical treatments are otherwise medically inadvisable). The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult patients with moderate to severe AD who are candidates for systemic therapy.

NCT ID: NCT06277206 Completed - Clinical trials for Pancreas Adenocarcinoma

A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic Adenocarcinoma

Start date: August 4, 2021
Phase:
Study type: Observational

To explore the potential utility of 18F-FAPI-04 PET/CT for pathologic response evaluation to systemic treatment in PDAC

NCT ID: NCT06277180 Recruiting - Surgery Clinical Trials

68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

This is a phase II clinical trial to evaluate the capability of 68Ga-labeled targeted covalent radiopharmaceutical (TCR) fibroblast activation protein inhibitor (FAPI) PET/CT to guide the surgical treatment of medullary thyroid carcinoma (MTC). The surgical extent of MTC is determined based on the lesion range revealed by 68Ga-TCR-FAPI PET/CT, with the main endpoint being 1-month post-surgical calcitonin level.

NCT ID: NCT06277167 Completed - Clinical trials for Healthy Participants

A Phase I Study in Healthy Participants

Start date: January 7, 2023
Phase: Phase 1
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase-I Clinical Study to Evaluate the Tolerability, Safety and PK Profiles of Human interferon alfa 1b inhalation solution in Healthy Adult Subjects after Administration of Single Ascending Doses and Multiple Ascending Doses